<code id='503FCE83B2'></code><style id='503FCE83B2'></style>
    • <acronym id='503FCE83B2'></acronym>
      <center id='503FCE83B2'><center id='503FCE83B2'><tfoot id='503FCE83B2'></tfoot></center><abbr id='503FCE83B2'><dir id='503FCE83B2'><tfoot id='503FCE83B2'></tfoot><noframes id='503FCE83B2'>

    • <optgroup id='503FCE83B2'><strike id='503FCE83B2'><sup id='503FCE83B2'></sup></strike><code id='503FCE83B2'></code></optgroup>
        1. <b id='503FCE83B2'><label id='503FCE83B2'><select id='503FCE83B2'><dt id='503FCE83B2'><span id='503FCE83B2'></span></dt></select></label></b><u id='503FCE83B2'></u>
          <i id='503FCE83B2'><strike id='503FCE83B2'><tt id='503FCE83B2'><pre id='503FCE83B2'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          focus

          author:fashion    - browse:568
          Influenza A virions
          F. A. Murphy/CDC

          Vir Biotechnology said Thursday that a long-acting antibody drug designed to protect healthy individuals from influenza A failed to do so in a nearly 3,000-person clinical trial.

          Volunteers who received the highest dose of the drug, known as VIR-2482, were only 16% less likely than the placebo group to develop symptomatic influenza A infections, as defined by trial criteria, over a seven-month period. The difference was not statistically significant.

          advertisement

          The results are a setback in broader efforts to develop better protective measures against both seasonal and potential pandemic influenza strains. In the short term, Vir and outside experts hoped VIR-2482 could provide additional annual protection for at-risk groups like older adults, as flu vaccines are often only modestly effective.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          entertainment